Promising New Drug!

My sister is a medical writer. She pointed me to some news this week, which may be of interest for those of us who have been affected by necrotizing fasciitis and, perhaps, those who will encounter the disease in the future:

Late today, the U.S. Food and Drug Administration approved Cubist Pharmaceuticals’ tedizolid phosphate (SIVEXTRO™) for the treatment of acute adult bacterial skin and skin structure infections, or ABSSSIs. Sivextro is indicated for infections caused by Gram-positive bacteria that include: Staphylococcus aureus (including methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) isolates), Streptococcus pyogenies

You can read more about Sivextro in Forbes magazine and here.

Tweet about this on TwitterShare on FacebookBuffer this pageShare on Google+Pin on PinterestShare on RedditDigg thisPrint this page